Financial Performance - The company's operating revenue for Q1 2023 was ¥87,304,768.91, representing a year-on-year increase of 20.08%[5] - The net profit attributable to shareholders was a loss of ¥14,231,619.55, reflecting a decline of 202.22% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥18,252,406.90, down 302.52% year-on-year[5] - Total operating revenue for Q1 2023 was CNY 87,304,768.91, an increase of 20.1% compared to CNY 72,706,319.65 in Q1 2022[21] - Net profit for Q1 2023 was a loss of CNY 14,231,619.55, compared to a profit of CNY 13,921,971.48 in Q1 2022[22] - The company reported a basic and diluted earnings per share of CNY -0.18 for Q1 2023, down from CNY 0.18 in Q1 2022[23] Expenses and Costs - Research and development expenses totaled ¥19,799,024.04, which is an increase of 73.02% compared to the previous year, accounting for 22.68% of operating revenue[6] - Total operating costs for Q1 2023 were CNY 101,776,392.04, up 65.5% from CNY 61,443,743.53 in Q1 2022[21] - Selling expenses rose to CNY 11,165,270.92 in Q1 2023, an increase of 49.5% from CNY 7,444,389.92 in Q1 2022[22] - The increase in management expenses was attributed to significant stock incentive costs and higher administrative staff salaries following the acquisition of Zhongyingjian[10] - The company experienced a significant increase in financial expenses, reporting CNY 652,480.86 in Q1 2023, compared to a gain of CNY -2,204,395.63 in Q1 2022[22] Cash Flow - The company reported a negative cash flow from operating activities of ¥33,872,953.18, which is not applicable for year-on-year comparison[5] - In Q1 2023, the company reported cash inflows from operating activities of ¥66,448,951.40, an increase of 31.9% compared to ¥50,345,556.32 in Q1 2022[24] - The cash outflows from operating activities totaled ¥100,321,904.58, up from ¥70,925,883.82 in the same period last year, resulting in a net cash flow from operating activities of -¥33,872,953.18[24] - The company achieved cash inflows from investment activities of ¥885,839,718.79, significantly higher than ¥527,414,596.75 in Q1 2022, with a net cash flow from investment activities of ¥31,629,037.84[25] - The company reported a net decrease in cash and cash equivalents of -¥8,743,172.73, compared to a much larger decrease of -¥1,309,037,546.86 in Q1 2022[25] - The ending balance of cash and cash equivalents was ¥358,699,458.77, compared to ¥256,106,060.25 in the same quarter last year[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,053,201,079.68, a slight decrease of 0.02% from the end of the previous year[6] - The company's total liabilities as of Q1 2023 were CNY 296,880,628.50, compared to CNY 287,751,134.70 in the previous year[19] - The total equity attributable to shareholders was CNY 1,756,320,451.18, a slight decrease from CNY 1,765,926,830.82 in Q1 2022[19] - The company reported accounts receivable of RMB 138,422,312.72, an increase from RMB 92,636,686.51 year-over-year[17] - The company’s fixed assets are valued at RMB 118,640,906.99, a slight decrease from RMB 119,807,372.24[17] - The company’s non-current assets total RMB 814,749,046.94, up from RMB 793,021,392.26 year-over-year[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,229[12] - The largest shareholder, Shanghai Dish Consulting, holds 27,771,000 shares, representing 35.62% of total shares[12] Market and Expansion - The company is actively expanding its domestic and overseas markets, increasing its sales team to enhance market share[10] - The company expanded its production capacity from 100,000 cages to 140,000 cages, leading to increased costs in depreciation, materials, and labor[9] Other Information - The company has no reported new products or technologies, market expansions, or mergers during this reporting period[15] - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous period[24] - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[26]

2022年年度报告摘要 公司代码：688265 公司简称：南模生物 上海南方模式生物科技股份有限公司 2022 年年度报告摘要 2022年年度报告摘要 第一节 重要提示 1 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2 重大风险提示 本公司已在本报告中详细阐述在生产经营过程中可能面临的相关风险,详情敬请查阅本报告 “第三节 管理层讨论与分析”之“四 风险因素”部分的相关内容。 3 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 4 公司全体董事出席董事会会议。 ...

Financial Performance - The company plans not to distribute profits for the year 2022, with no cash dividends or stock bonuses, and will carry forward the undistributed profits to the next year[7]. - The company has not achieved profitability since its listing[5]. - The company's operating revenue for 2022 was CNY 302,965,239.57, representing a year-on-year increase of 10.06%[25]. - The net profit attributable to shareholders decreased by 108.87% to a loss of CNY 5,399,643.49[28]. - The net cash flow from operating activities was CNY 18,893,416.66, down 83.05% compared to the previous year[29]. - Basic and diluted earnings per share fell to -CNY 0.07, a decrease of 106.73%[30]. - The company reported a total revenue of 30,242.88 million yuan for its main business in 2022, representing a year-on-year growth of 10.52%[57]. - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was approximately CNY -29.56 million, a year-on-year decrease of 156.33%[41]. - The company achieved a 68.19% year-on-year increase in overseas revenue, amounting to 32.69 million yuan, despite challenges from COVID-19 and high temperatures affecting air freight[52]. Risk Management - The company has detailed the potential risks faced during its operations in the report[5]. - The company has a comprehensive risk statement regarding forward-looking statements in the annual report[8]. - There are no non-operating fund occupations by controlling shareholders or related parties[9]. - The company is exposed to regulatory risks related to the management of experimental animals, especially as regulations become stricter[128]. - The company faces risks related to changes in tax incentives and government subsidy policies, which could adversely affect profitability[131]. - The company must maintain high-quality standards and stable product quality to meet the dynamic demands of clients, as customer loyalty is high for verified strains[76]. Research and Development - Research and development expenses accounted for 21.7% of operating revenue, an increase of 4.28 percentage points from the previous year[26]. - R&D expenses totaled 65.76 million yuan, a year-on-year increase of 37.14%, contributing to a decline in profits for the period[44]. - The company has developed over 15,000 models, including more than 8,600 standardized models, showcasing its extensive experience in gene-modified animal model development[60]. - The company has developed four core technologies in gene-modified animal model construction, including CRISPR/Cas system gene editing technology and ES cell targeting technology[92]. - The company is focused on optimizing CRISPR/Cas and ES cell targeting techniques to improve animal model quality[98]. - The company is committed to optimizing gene editing parameters to improve success rates and reduce off-target risks, while exploring multi-gene modification techniques[191]. Market Expansion - The company is expanding its market presence in Europe, targeting a 15% market share by the end of 2023[18]. - The company is actively expanding its sales channels, establishing offices in Europe and Japan, and collaborating with distributors in Singapore and South Korea to enhance its international presence[52]. - The company plans to enhance its domestic market share and expand its international market presence through increased sales team investments[28]. - The company is deepening its domestic market presence while accelerating its global expansion, particularly in Europe and the U.S.[194]. Corporate Governance - The audit report issued by Zhonghui Certified Public Accountants is a standard unqualified opinion[6]. - The financial report is confirmed to be true, accurate, and complete by the responsible persons[7]. - The company has not implemented any special arrangements for corporate governance[10]. Operational Efficiency - The gross margin improved to 60%, up from 55% in the previous year, reflecting better operational efficiency[16]. - The company faced increased production costs due to expanded scale and rising expenses in materials, energy, and labor[28]. - The company reported significant increases in management and sales expenses due to expansion efforts and rising operational costs[28]. - The company expanded its production capacity to approximately 140,000 cage positions across five production and R&D bases[28]. Strategic Acquisitions - A strategic acquisition of a smaller biotech firm was completed, enhancing the company's R&D capabilities and expected to generate $5 million in cost synergies[14]. - The company acquired 100% equity of Zhongyingjian through a debt acquisition, focusing on core assets related to industrial land and facilities[33]. - The company completed the acquisition of 100% equity in Shanghai Zhongying Health Technology Co., Ltd. for RMB 395.73 million using raised funds, with the business registration change completed by the end of the reporting period[179]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 30%[16]. - Future guidance includes an EBITDA margin target of 25% for the upcoming fiscal year[18]. - The company plans to enhance market development efforts and improve project completion efficiency to restore revenue growth as external uncertainties decrease[58].

Financial Performance - The company's operating revenue for Q3 2022 was ¥85,440,761.93, representing a year-on-year increase of 25.78%[5] - The net profit attributable to shareholders was -¥4,959,326.26, a decrease of 108.15% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,643,704.76, reflecting a decline of 124.09%[6] - Basic earnings per share for the current reporting period was -105.77, with diluted earnings per share also at -105.77, reflecting a decrease in net profit[11] - The net profit for Q3 2022 was -75,071.53 RMB, a significant decrease compared to 38,727,634.07 RMB in Q3 2021[25] - The total profit for Q3 2022 was -3,737,828.96 RMB, down from 43,878,279.60 RMB in the same period last year[25] - Operating profit for Q3 2022 was -3,594,726.72 RMB, compared to 44,123,180.62 RMB in Q3 2021[25] - The total comprehensive income for Q3 2022 was 356,678.47 RMB, down from 38,725,802.05 RMB in Q3 2021[26] - Basic and diluted earnings per share for Q3 2022 were both 0.00 RMB, compared to 0.66 RMB in Q3 2021[26] Research and Development - The total R&D investment amounted to ¥21,544,964.23, which accounted for 25.22% of operating revenue, an increase of 4.82 percentage points year-on-year[6] - Total R&D investment for the current reporting period was 55.48 million, an increase from 32.78 million for the year-to-date[11] - Research and development expenses for the first three quarters of 2022 amounted to CNY 44,957,893.67, compared to CNY 33,859,549.58 in 2021, reflecting a year-over-year increase of approximately 32.7%[23] - The company is focusing on expanding its research and development efforts, as evidenced by the increased R&D expenses, which may lead to new product developments in the future[23] Cash Flow and Assets - The cash flow from operating activities was -¥17,163,740.37, indicating a significant decline of 133.77%[6] - The company's cash and cash equivalents decreased to CNY 251,303,400.28 from CNY 1,566,200,232.11, a decline of about 84%[18] - Cash flow from operating activities for the first nine months of 2022 was -17,163,740.37 RMB, a decline from 50,820,389.56 RMB in the same period of 2021[29] - Cash flow from investment activities in the first nine months of 2022 was -1,057,536,533.39 RMB, compared to a positive cash flow of 21,708.78 RMB in the previous year[29] - The cash and cash equivalents at the end of Q3 2022 were 251,278,400.28 RMB, a decrease from 115,526,472.92 RMB at the end of Q3 2021[30] - The company reported a cash inflow from operating activities of 190,703,456.29 RMB for the first nine months of 2022, down from 202,626,670.51 RMB in the same period of 2021[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,008[13] - The largest shareholder, Shanghai Dish Consulting Co., Ltd., holds 27,771,000 shares, representing 35.6% of total shares[13] - The second-largest shareholder, Shanghai Technology Venture Capital Co., Ltd., holds 10,760,733 shares, accounting for 13.8%[13] Operational Challenges - The company faced challenges in revenue growth due to the impact of COVID-19 control measures in Shanghai, affecting new orders and revenue recognition[10] - The company's operating revenue growth was low due to COVID-19 control measures in Shanghai, leading to a decrease in cash inflow from operating activities[11] - The company is facing uncertainties in its external operating environment due to the ongoing impact of COVID-19, which may affect logistics and transportation[16] - The company has implemented enhanced epidemic prevention measures and emergency plans to mitigate the adverse effects of COVID-19[17] Costs and Liabilities - Total operating costs for the first three quarters of 2022 were CNY 234,245,219.39, up from CNY 150,123,769.13 in 2021, indicating a significant increase of about 56%[23] - Total liabilities as of September 30, 2022, were CNY 368,227,444.67, up from CNY 180,396,846.80 in 2021, which is an increase of approximately 103.5%[20] - The company's inventory as of September 30, 2022, was CNY 14,674,652.20, slightly down from CNY 15,011,078.34 in 2021, indicating a decrease of about 2.2%[18] - The non-current assets totaled CNY 676,689,973.38 as of September 30, 2022, compared to CNY 203,350,577.75 at the end of 2021, representing a significant increase of approximately 232%[19] Production Capacity - The company expanded its production capacity from 50,000 cages to 110,000 cages, leading to increased costs in depreciation and material expenses[10] - Management expenses increased significantly due to the new Shanghai Novartis base being in the renovation and trial operation phase, resulting in high rental and utility costs[10]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 2022 年第三季度报告 证券代码：688265 证券简称：南模生物 上海南方模式生物科技股份有限公司 2022 年第三季度报告 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 比上年同 | | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 85,440,761.93 | 25.78 | 215,445,3 ...

Financial Performance - The company reported a half-year revenue of 688 million RMB, representing a year-on-year increase of 15%[1] - The net profit for the first half of 2022 was 120 million RMB, up 10% compared to the same period last year[1] - The company reported a revenue of RMB 100 million for the first half of 2022, representing a 20% increase compared to the same period last year[14] - The company's operating revenue for the first half of 2022 was ¥130,004,584.97, representing a 6.73% increase compared to ¥121,804,164.50 in the same period last year[20] - The net profit attributable to shareholders decreased by 81.64% to ¥4,884,254.73 from ¥26,604,883.26 year-on-year[20] - The company achieved a total R&D investment of 23.41 million yuan, representing a 17.05% increase compared to the previous year's 20.00 million yuan[52] - The company achieved a revenue of approximately 130.00 million, representing a year-on-year growth of 6.73%[69] User Growth and Market Expansion - User data indicates a growth in active users by 25%, reaching a total of 1.5 million users[1] - User data showed an increase in active users by 15%, reaching a total of 1.5 million users by June 30, 2022[14] - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[1] - The company plans to expand its market presence in Europe and North America, targeting a 10% market share in these regions by the end of 2023[14] - The company provided a future outlook, projecting a revenue growth of 25% for the second half of 2022, driven by new product launches and market expansion[14] Research and Development - The company has allocated 50 million RMB for R&D in the next fiscal year to enhance its product offerings[1] - Investment in R&D increased by 30% year-over-year, focusing on gene editing technologies and genetically modified animal models[14] - The company's R&D expenditure accounted for 18.01% of operating revenue, an increase of 1.59 percentage points compared to 16.42% in the previous year[21] - The company has developed over 14,000 models for gene function research and drug development in various disease areas, including tumors and metabolic diseases[29] - The company has independently developed over 8,000 standardized models and provided more than 6,400 customized models to clients, showcasing its extensive experience in gene-modified animal model development[29] - The company has established a comprehensive R&D system and core technology platform for genetically modified animal models, focusing on CRISPR/Cas and ES cell targeting technologies[43][46] Product Development - New product development includes a cutting-edge biotechnological solution expected to launch in Q4 2022, projected to increase revenue by 30%[1] - A new product line related to immune checkpoint inhibitors is expected to launch in Q4 2022, with projected sales of RMB 50 million in the first year[14] - The company has developed a mouse model with a 3-4 times increase in mature oocyte quantity through its self-developed mouse ovulation induction technology[49] - The company has established a spontaneous obesity and insulin resistance model by knocking out the protein related to pancreatic lipase, which can be used for drug screening[48] Operational Challenges - The company faced significant challenges due to COVID-19, impacting revenue recognition and increasing production costs[22] - The company reported a significant increase in operational costs due to expanded production scale and employee compensation during the pandemic[22] - The ongoing uncertainty of the COVID-19 pandemic continues to pose risks to the company's operations, particularly in logistics and client interactions[90] - The company faced significant revenue impacts due to the COVID-19 pandemic, particularly in the Shanghai area, but has since resumed normal operations[69] Financial Management - The net cash flow from operating activities was -¥33,252,222.31, a decline of 204.79% compared to the previous year[22] - The company recognized government subsidies of CNY 2.67 million during the reporting period, which may impact future profitability if such subsidies are not continued[94] - The company reported a net cash outflow from investment activities of approximately CNY 1.32 billion, primarily due to significant investments in structured deposits[100] - The company has confirmed that there are no major changes in the integrity status of the company and its controlling shareholders during the reporting period[190] Sustainability and Social Responsibility - The company emphasizes its commitment to sustainability and social responsibility initiatives, with a budget of 10 million RMB for community projects[1] - The company has established an environmental management system and implemented measures for waste disposal and pollution management[128] - The company promotes energy conservation and waste reduction initiatives, including a paperless office policy and reduced plastic usage[130] - The company has taken steps to ensure compliance with commitments related to shareholding and management practices, reflecting a focus on corporate governance[135] Corporate Governance and Shareholder Commitments - The actual controller and major shareholders committed to a share lock-up period of 42 months from the date of listing, ensuring stability in shareholding[135] - The company will ensure that any share reduction complies with the relevant laws and regulations, including disclosure requirements[146] - The company has committed to avoiding any form of competition with its subsidiaries and will take effective measures to prevent such activities if listed on domestic stock exchanges[179] - The commitments made by the actual controllers are irrevocable and will remain effective throughout their tenure[182]

Financial Performance - The company's operating revenue for Q1 2022 was ¥72,706,319.65, representing a year-on-year increase of 33.88%[4] - The net profit attributable to shareholders was ¥13,921,971.48, reflecting a year-on-year growth of 17.64%[4] - Total operating revenue for Q1 2022 was ¥72,706,319.65, an increase of 33.9% compared to ¥54,305,590.46 in Q1 2021[17] - Net profit for Q1 2022 reached ¥13,921,971.48, representing a 17.6% increase from ¥11,834,124.97 in Q1 2021[18] - The company reported a total comprehensive income of ¥13,903,726.09 for Q1 2022, compared to ¥11,834,124.97 in Q1 2021[19] Research and Development - R&D investment totaled ¥11,443,479.93, which is an increase of 36.37% compared to the previous year, indicating enhanced R&D capabilities[4][7] - Research and development expenses in Q1 2022 amounted to ¥11,443,479.93, a significant rise of 36.5% compared to ¥8,391,567.71 in Q1 2021[18] - The proportion of R&D investment to operating revenue was 15.74%, an increase of 0.29 percentage points[5] Cash Flow and Liquidity - The net cash flow from operating activities was -¥20,580,327.50, a significant decrease of 803.37% year-on-year, primarily due to slower customer payment speeds and increased operational expenses[4][7] - The total cash inflow from operating activities for Q1 2022 was ¥50,345,556.32, a decrease of 9.4% compared to ¥55,275,599.11 in Q1 2021[21] - The net cash outflow from operating activities was ¥20,580,327.50, contrasting with a net inflow of ¥2,925,966.01 in the same period last year[21] - The ending balance of cash and cash equivalents was ¥256,106,060.25, a decrease from ¥64,618,665.71 in the same quarter last year[22] - The cash flow from operating activities was negatively impacted by increased payments to employees, which rose to ¥35,398,217.71 from ¥28,191,409.02 in Q1 2021[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,942,015,807.46, a decrease of 1.12% from the end of the previous year[5] - The company's total assets as of Q1 2022 were ¥1,942,015,807.46, slightly down from ¥1,964,057,227.03 in the previous quarter[15] - Total liabilities decreased to ¥153,430,872.61 in Q1 2022 from ¥180,396,846.80 in Q1 2021[15] - The company's equity attributable to shareholders increased to ¥1,788,584,934.85 in Q1 2022, compared to ¥1,783,660,380.23 in Q1 2021[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,277[9] - The company’s major shareholders include various investment funds, with significant holdings in common stock[11] - The report indicates that the company has not received any declarations of related party transactions among shareholders, maintaining transparency[11] Operational Challenges - The company is facing operational challenges due to COVID-19, impacting logistics and client operations, which may affect future performance[12] - The company has implemented measures to mitigate the impact of the pandemic on its operations, ensuring production continuity[12] Earnings Per Share - Basic earnings per share (EPS) decreased by 10.00% to ¥0.18, while diluted EPS remained unchanged at ¥0.18[4] - The basic earnings per share for Q1 2022 was ¥0.18, down from ¥0.20 in Q1 2021[19]

Financial Performance - The company reported a significant increase in revenue for the fiscal year 2021, achieving a total of RMB 500 million, representing a year-over-year growth of 25%[16]. - The company's operating revenue for 2021 was CNY 275.27 million, representing a year-on-year growth of 40.31%[23]. - Net profit attributable to shareholders increased by 36.59% to CNY 60.86 million, while the net profit after deducting non-recurring gains and losses grew by 60.36% to CNY 52.48 million[26]. - The net cash flow from operating activities reached CNY 111.46 million, an increase of 88.58% compared to the previous year[28]. - The company achieved operating revenue of CNY 275.27 million, a year-on-year increase of 40.31%[136]. - The net profit attributable to shareholders reached CNY 60.86 million, up 36.59% year-on-year[136]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 52.48 million, reflecting a growth of 60.36%[136]. - The gross profit margin may fluctuate due to the diverse nature of the company's main business, which includes genetically modified animal models and related technical services[131]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 2.57 CNY per 10 shares, totaling approximately 20,036,622.84 CNY, which represents 32.92% of the net profit attributable to shareholders for 2021[6]. - The total share capital used for the dividend calculation is 77,963,513 shares, with the actual amount to be confirmed on the dividend record date[6]. - The company does not plan to increase capital reserves or issue bonus shares, with remaining undistributed profits carried forward to the next year[6]. Research and Development - The R&D expenditure for 2021 was RMB 150 million, accounting for 30% of total revenue, reflecting the company's commitment to innovation[16]. - The company maintained a research and development investment ratio of 17.42% of operating revenue[24]. - The company is investing in the development of humanized models for drug testing, which is anticipated to improve the accuracy of preclinical studies[16]. - The company has developed over 7,200 standardized models, including 456 humanized gene-modified models for tumor immunotherapy and 133 spontaneous tumor models for targeted therapy[98]. - The company has established a comprehensive animal model evaluation system covering various disease models for both tumor and non-tumor drug efficacy evaluation[111]. - The company is focusing on gene editing technology to reduce costs and improve efficiency in gene modification research[104]. Market Expansion and Strategy - The company plans to expand its market presence in Asia and Europe, targeting a 15% increase in market share by the end of 2022[16]. - Strategic acquisitions are being considered to enhance the company's research capabilities and product offerings, with a budget allocation of RMB 100 million for potential mergers and acquisitions[16]. - The company aims to enhance its model resource library to meet diverse market demands and maintain its competitive advantage domestically[101]. - The company is committed to deepening its domestic market presence while expanding into overseas markets, particularly in Europe and the U.S.[183]. Operational Efficiency - The company reported a gross margin of 60% for 2021, indicating strong operational efficiency and cost management[16]. - The company has successfully established a one-stop service system from gene-modified animal model construction to phenotypic analysis and pharmacological efficacy evaluation[25]. - The company has a mature SPF-level experimental animal production and operation management system, ensuring compliance with international management standards[81]. Risks and Compliance - The company has detailed the risks it may face in its production and operation processes in the report[4]. - The company faces risks related to the rapid evolution of gene editing technologies, particularly if the current CRISPR/Cas technology is replaced without timely adaptation[118]. - The company must ensure compliance with strict regulations regarding the management of experimental animals to avoid potential penalties[126]. Human Resources - The company emphasizes the importance of talent development, with 89.47% of R&D personnel holding a bachelor's degree or higher[45]. - The company has a research and development team of 76 people, accounting for 14.93% of total employees, with an average salary of CNY 21.81 million[106]. - A talent cultivation and recruitment system is being established to attract high-quality professionals in various fields, enhancing the overall competency of the team[193]. Customer Relationships and Sales - The company has established strong relationships with over 600 research clients and more than 400 industrial clients, enhancing customer stickiness and resource advantages[116]. - The sales and marketing teams are collaborating to enhance customer satisfaction and loyalty by improving service quality and expanding customer acquisition channels, particularly targeting CROs and innovative pharmaceutical companies[189]. - The company is enhancing its customer relationship management by establishing independent sales teams for different customer segments and creating customer profiles to better meet their research needs[189]. Corporate Governance - The company is committed to continuous improvement in corporate governance to protect shareholder rights and ensure effective decision-making processes[195]. - The company held one shareholders' meeting during the reporting period, which complied with legal regulations and had valid attendance and voting procedures[198].